A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp When Administered as a Bolus in a Continuous Subcutaneous Infusion Regimen in Subjects With Type 1 Diabetes
Phase of Trial: Phase I
Latest Information Update: 01 Feb 2017
Price : $35 *
At a glance
- Drugs Insulin aspart (Primary)
- Indications Type 1 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Novo Nordisk
- 16 Sep 2016 Results presented at the 52nd Annual Meeting of the European Association for the Study of Diabetes
- 10 Mar 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrial,gov record.
- 28 Feb 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrial,gov record.